佐力药业(300181) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥453,488,563.91, an increase of 0.90% compared to the same period last year, while year-to-date revenue reached ¥1,464,947,132.50, up 8.97% year-on-year [4]. - Net profit attributable to shareholders for Q3 2023 was ¥89,203,600.05, representing a 29.14% increase year-on-year, and year-to-date net profit was ¥286,865,191.49, up 40.65% [4]. - The basic earnings per share for Q3 2023 was ¥0.1272, a 12.07% increase compared to the same period last year, with year-to-date diluted earnings per share also at ¥0.4090, up 22.05% [4]. - Total operating revenue for the current period reached CNY 1,464,947,132.50, an increase of 8.95% compared to CNY 1,344,402,602.13 in the previous period [20]. - Net profit for the current period was CNY 292,583,698.54, representing a 36.24% increase from CNY 214,596,952.02 in the previous period [21]. - Earnings per share (EPS) increased to CNY 0.4090 from CNY 0.3351, marking a growth of 22.05% [22]. Assets and Liabilities - The company's total assets at the end of Q3 2023 were ¥3,543,470,789.72, a decrease of 2.63% from the end of the previous year [4]. - The company’s equity attributable to shareholders at the end of Q3 2023 was ¥2,667,380,677.87, a decrease of 1.35% from the end of the previous year [4]. - The total liabilities decreased to CNY 830,182,267.56 from CNY 879,192,754.90, a reduction of 5.57% [22]. - The total equity attributable to shareholders of the parent company was CNY 2,667,380,677.87, down from CNY 2,703,749,664.26, a decline of 1.34% [22]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥223,951,981.61, an increase of 15.50% compared to the same period last year [4]. - The net cash inflow from operating activities was CNY 223.95 million, an increase of CNY 30.05 million or 15.50% year-on-year [11]. - The net cash outflow from investing activities was CNY 115.15 million, an increase of CNY 52.45 million or 83.66% year-on-year, primarily due to reduced cash inflow from financial product investments and increased long-term asset investments [11]. - The net cash outflow from financing activities was CNY 170.68 million, an increase of CNY 4.61 million or 2.78% year-on-year, mainly due to increased dividend distribution and short-term borrowings [11]. - The cash inflow from operating activities totaled CNY 1,634,268,265.69, compared to CNY 1,358,686,568.10, indicating an increase of 20.24% [23]. - The cash outflow for debt repayment was CNY 204,830,690.32, a decrease of 7.7% from CNY 222,000,000.00 in the same quarter last year [24]. Investments and Expenses - The company reported a significant increase in construction in progress, which rose to ¥149,094,700, an increase of 91.01% due to ongoing investments in smart traditional Chinese medicine production base and new pharmaceutical industrialization projects [8]. - Research and development expenses rose to CNY 58,183,284.31, up from CNY 50,502,876.94, reflecting a growth of 15.24% [20]. - The company experienced a 46.13% decline in revenue from formula granules, totaling ¥27,513,000, due to ongoing registration processes with national and provincial standards [9]. - The company recorded a significant increase in interest income, reaching CNY 17,342,268.01 compared to CNY 1,791,225.26 in the previous period [21]. Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 40,247 [13]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, with 129,890,463 shares pledged [13]. Other Information - The company did not undergo an audit for the Q3 report [25]. - The report was issued by the board of directors on October 20, 2023 [26].